Full Year 2024 Results Key Financial Results Revenue: US$9.29m (up 69% from FY 2023).
the Company’s lead autoimmune program with potential to transform treatment across a broad spectrum of autoimmune and inflammatory diseases Advanced research and development of CUE-501 as lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback